12.04.2018
STRATEC Biomedical AG DE000STRA555
DGAP-News: STRATEC intends to modify its legal form to that of a European company
DGAP-News: STRATEC Biomedical AG / Key word(s): Miscellaneous
STRATEC intends to modify its legal form to that of a European company
12.04.2018 / 08:17
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC intends to modify its legal form to that of a European company
Birkenfeld, April 12, 2018
The Management Board and the Supervisory Board of STRATEC Biomedical AG have
decided to propose the transformation of STRATEC Biomedical AG into a
European company (Societas Europaea, SE), to be known in future as STRATEC
SE, at the Annual General Meeting on May 30, 2018. As part of this change,
the name supplement "Biomedical" will be dropped in the future.
In the opinion of the Management Board and the Supervisory Board, the
planned change of legal form is in keeping with STRATEC's identity as an
internationally oriented company. The internationalization of STRATEC has
further accelerated in recent years, in particular through the subsidiaries
acquired and founded in other member states of the European Union, as well
as through the revenue growth achieved with international customers. As of
December 31, 2017, group-wide, 57% of employees are based abroad. In
addition, for the fiscal year 2016, 87% of sales revenue was generated with
customers outside of Germany. The transformation into an SE is therefore a
consistent step which also offers the possibility of further optimizing
STRATEC structures to the expected future international corporate growth.
With the transformation into an SE, the shareholders of STRATEC Biomedical
AG automatically become shareholders of STRATEC SE. The rights of the
shareholders will remain unchanged.
The conversion of legal form requires the approval of the shareholders. This
is planned to be secured at the Annual General Meeting on May 30, 2018.
The shareholders of STRATEC Biomedical AG will receive detailed information
on this planned legal form transformation with the invitation to the Annual
General Meeting.
About STRATEC
STRATEC Biomedical AG ( www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. Furthermore, the company offers sample
preparation solutions, integrated laboratory software, and complex
consumables for diagnostic and medical applications. STRATEC covers the
entire value chain - from development to design and production through to
quality assurance.
The partners market the systems, software and consumables, in general
together with their own reagents, as system solutions to laboratories, blood
banks, and research institutes around the world. STRATEC develops its
products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange.
Further information is available from:
STRATEC Biomedical AG
Jan Keppeler, Investor Relations & Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-6515
Fax: +49 7082 7916-9190
[email protected]
www.stratec.com
---------------------------------------------------------------------------
12.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: [email protected]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
673633 12.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
STRATEC Biomedical AG ISIN: DE000STRA555 können Sie bei EQS abrufen
Medtech , STRA55 , SBS , XETR:SBS